CASE REPORT
A 55 year old female patient, with no significant past medical/surgical history except for a total hysterectomy (2011) and no known drug and/or food allergies, non-smoker, nonalcoholic, presented to the Emergency Unit with complaints of shortness of breath, difficulty lying flat and abdominal pain for 2 weeks duration. Vitals were temperature 97.2 o F, pulse 72/min, respiratory rate 20/min, blood pressure 90/60mmHg and SPO2 98% on room air.
Patient gave a 3-4 week history of "swollen lymph nodes around the neck" for which she saw the district doctor who requested a complete blood count (results: WBC-87,100mm 3 , Hb-13.4g/dl, HCT-37%, PLT-154,000/uL) and ultrasonography which indicated splenomegaly.
She received O2 therapy 5L by face mask, was referred and admitted to the female medical ward.
On physical examination, multiple enlarged firm non-tender lymph nodes were noted around the scalp and both pre-auricular areas, cervical, axillary, and inguinal area. Large tender mass noted to the left lower quadrant (? enlarged spleen), pitting edema to the lower extremities. Patient was alert and oriented to time, person and place, and had good muscle strength to all extremities. Labs done as shown in Table 1 Arrangements were made and patient was flown to Trinidad.
At Trinidad, patient was assessed and it was indicated that she required five sessions of chemotherapy. She received the CHOP regimen using doxorubicin 70mg, vincristine 2mg, cyclophosphamide 1gm, after pre-medicated with emend (aprepitant ®) 125mg, granisetron 3mg and dexamethasone 12mg. A normal left ventricular function was confirmed with echocardiography before initiating chemotherapy. Patient had minimal complaints post-therapy, and tolerated the regimen well. Presently, she has received three doses of her chemotherapy and is awaiting the remaining two doses.
DISCUSSION
Painless lymphadenopathy in an adult carries a red flag as this in most cases is seen with chronic inflammation (chronic lymphadenitis), metastatic carcinoma, or lymphoma (7). Since its discovery in the 1970s, studies have elucidated the infection and pathogenesis of HTLV-I.
It is known that the virus can be transmitted through sexual contact, from mother to child, and through contaminated blood products. An estimate of 10 to 20 million people is infected worldwide with predominance in Japan, parts of Africa, the Caribbean and South America (8) . Early-life exposure to the HTLV-I virus, through mother-to-infant transmission, has been postulated to pose the greatest risk for subsequent development of ATL (9).
Evidence using serological and molecular biological studies showed convincing association of HTLV-I and ATL (10). Other evidence from epidemiological studies confirms the role of HTLV-I in ATL, HTLV-associated myelopathy/tropical spastic paresis (HAM/TSP) and uveitis (11) (12) (13) . However, a majority of infected people remain asymptomatic; it is not yet fully understood why some infected persons develop associated diseases whereas others do not (14) .
There are several types of HTLV-I-induced adult T-cell leukaemia/lymphoma (ATL):
acute, lymphomatous, chronic, and smouldering, with a proportion of 55%, 20%, 20% and 5% correspondingly (15) . A fifth type of ATL has been described: primary cutaneous tumoral ATL (18) . Almost all patients with ATL present with lymphadenopathy and 50% have interferon-α with zidovudine, intensive chemotherapy plus granulocyte colony-stimulating factor support, and allogenic haematopoietic stem cell transplantation (19, 23) . The rationale for therapy with CHOP can be explained by the reduction in tumor burden. An improvement in survival is achieved when antiretroviral therapy and oral etoposide was used following treatment with CHOP, IFN-α, and an antinucleoside (zidovudine or zalcitabine) (25) .
Nevertheless, the median survival of patients with acute, lymphomatous, and progressing chronic ATL remained low: less than 18 months in most reports (19, 24) . Novel approaches include histone deacetylation inhibitors, monoclonal antibodies, and proteasome inhibitors, but their added value remains to be established (19) .
CONCLUSION
The spectrum of manifestations of HTLV infection remains broad and diagnosis is frequently delayed as it can range from an asymptomatic patient to one with generalized non-tender lymphadenopathy as seen in our case. Early diagnosis, especially in pregnant women can help reduce the incidence of HTLV infection and ATL, which develops decades after.
Although ATL is an aggressive neoplasia with a poor prognosis, successful treatment has been reported. The presence of Ki67 antigen, increased LDH, serum calcium, soluble IL-2 receptor, neuron-specific enolase, thymidine kinase and β2-microglobulin are associated with poor prognosis. Further studies on arresting the transformation of infected T-cells, and/or interrupting mother-to-infant transmission where breastfeeding is unavoidable would be a better approach in preventing HTLV-associated ATL. 
